MBX — MBX Biosciences, Inc. Stock Price, Chart & AI Report

Positive Apr 3, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MBX Biosciences announced the appointment of Karen Basbaum as Chief Business Officer and issued her an equity inducement award of 130,000 non-qualified stock options with an exercise price of $32.29 per share. The options vest over four years with a 10-year term, approved by the board as a material inducement for her employment.

MBX Chief Business Officer appointment equity inducement award stock options precision peptide therapies endocrine and metabolic disorders canvuparatide Phase 3 trial

Sentiment note

The appointment of a new Chief Business Officer signals organizational growth and strategic advancement. The company is progressing with Phase 3 trials for canvuparatide and has an active obesity portfolio in development, indicating positive momentum in pipeline advancement and commercial readiness.

Neutral Dec 3, 2025 • 16:10 UTC The Motley Fool • Jonathan Ponciano

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

MPM BioImpact sold its entire 1.3 million share stake in MBX Biosciences, worth $14.8 million, during Q3 2025, just before the company's pivotal clinical trials and potential key milestones in 2026.

MBX biotech clinical trials precision peptide therapies institutional investment

Sentiment note

Despite the fund's exit, the company has positive Phase 2 results, $391.7 million in cash, and upcoming Phase 3 trials for multiple drug candidates, indicating potential but also significant uncertainty

Neutral Sep 25, 2025 • 01:15 UTC GlobeNewswire Inc. • Katie Beach Oltsik

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences is conducting a public offering of 11,108,055 shares at $18.00 per share, expecting to raise approximately $199.9 million to support its precision peptide therapy development for endocrine and metabolic disorders.

MBX AMJB JPM JPMPC public offering biopharmaceutical peptide therapy endocrine disorders

Sentiment note

The company is raising capital through a standard public offering, which indicates financial strategy for growth rather than a crisis or exceptional success

Neutral Sep 22, 2025 • 20:14 UTC Benzinga • Globe Newswire

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences has filed a registration statement for a proposed public offering of 10 million common stock shares, with an additional option for underwriters to purchase 1.5 million shares. The offering is subject to market conditions and has major investment banks as joint book-running managers.

MBX AMJB JPM JPMPC public offering biopharmaceutical peptide therapies endocrine disorders

Sentiment note

The company is conducting a standard public offering to raise capital, which is a typical financing strategy for clinical-stage biopharmaceutical companies. The neutral sentiment reflects the routine nature of the offering without indicating significant positive or negative implications.

Positive Sep 22, 2025 • 11:00 UTC GlobeNewswire Inc. • Mbx Biosciences

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences reported successful Phase 2 trial results for canvuparatide, a potential once-weekly treatment for hypoparathyroidism, with 63% responder rate at 12 weeks and 79% at 6 months, with plans to initiate Phase 3 trials in 2026.

MBX hypoparathyroidism canvuparatide clinical trial peptide therapy endocrine disorder

Sentiment note

Achieved primary endpoint in Phase 2 trial with statistically significant results, no serious adverse events, and positive outlook for Phase 3 development

Positive Jun 10, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

MBX Biosciences, a clinical-stage biopharmaceutical company, announced presentations at the American Diabetes Association's 85th Scientific Sessions. The presentations will focus on the safety, pharmacokinetics, and pharmacodynamics of their investigational drug MBX 1416, a GLP-1 receptor antagonist, for the treatment of post-bariatric hypoglycemia.

MBX MBX Biosciences GLP-1 receptor antagonist post-bariatric hypoglycemia

Sentiment note

The article highlights the company's upcoming presentations at a major scientific conference, which suggests progress in the development of their investigational drug MBX 1416 for the treatment of post-bariatric hypoglycemia, a serious condition with no approved therapies.

Positive Oct 28, 2024 • 12:00 UTC GlobeNewswire Inc. • N/A

MBX Biosciences to Participate in Upcoming November Investor Conferences

MBX Biosciences, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences, including the Guggenheim Inaugural Healthcare Innovation Conference, Stifel 2024 Healthcare Conference, and Jefferies London Healthcare Conference.

MBX MBX Biosciences investor conferences biopharmaceutical company

Sentiment note

The article announces the company's participation in upcoming investor conferences, which suggests it is actively engaging with the investment community and likely has positive developments to share.

Positive Sep 30, 2024 • 12:00 UTC GlobeNewswire Inc. • N/A

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

MBX Biosciences announced the rationale and design of its Phase 2 Avail™ trial for MBX 2109, a potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism. The trial aims to evaluate the safety, pharmacokinetics, and efficacy of MBX 2109 in normalizing serum calcium levels and reducing the need for active vitamin D and calcium supplementation.

MBX MBX Biosciences MBX 2109 hypoparathyroidism Phase 2 trial

Sentiment note

The article highlights the company's progress in developing a potential treatment for hypoparathyroidism, with a focus on the rationale and design of the Phase 2 Avail™ trial for MBX 2109. The positive sentiment is based on the company's efforts to address the underlying pathophysiology of the disease and the potential for MBX 2109 to provide consistent and convenient relief for patients.